Rituximab Skin Reaction;Skin Hyperpigmentation with Minocycline;Baclofen-Induced Psychosis;Tyrosine Kinase Inhibitors and Hypothyroidism;Myoclonus with Low-Dose Hydromorphone;Hyponatremia with Newest Antidepressant;Lingual Lesions with Orally Disintegrating Risperidone;Quetiapine-Induced Erythema Multiforme Minor

Abstract

The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the FDA's medWatch program (800-FDA-1088). If you have reported an interesting preventable ADR to medWatch, please consider sharing the account with our readers. Write to Dr. Shuster at ISMP, 1800 Byberry Road, Suite 810, Huntingdon Valley, PA 19006 (call 215-947-7797; fax [phone]; E-mail: [e-mail]). Your report will be published anonymously unless otherwise requested. This feature is provided by the Institute for Safe Medication Practices in cooperation with the FDA's medWatch Program and Temple University School of Pharmacy. ISMP is an FDA medWatch partner.